published, an estimation of around 1 year is considered standard among experts, based on extrapolations from clinical trials and retrospective studies evaluating survival outcomes on components of this treatment regimen. [3] [4] [5] [6] The reasonably poor prognosis associated with this condition has prompted ongoing efforts in the discovery of additional or alternative therapeutics, including various inhibitors of the renin-angiotensin-aldosterone system (RAAS), 7, 8 newer diuretics, 9, 10 and surgical repair. [11] [12] [13] In these research efforts, a somewhat neglected therapeutic target is the natriuretic peptide system. Brain natriuretic peptide (BNP1-32) is an active component of this system. Binding to natriuretic peptide receptor A (NPR-A) causes activation of guanylyl cyclase that converts the cytosolic nucleotide guanosine triphosphate (GTP)
into cyclic guanosine monophosphate (cGMP). From there, cGMP acts as an intracellular secondary messenger and causes diuresis, natriuresis, vasodilation, and RAAS antagonism. These are desirable properties to combat the progression of CHF and, indeed, experimental animal studies, [14] [15] [16] [17] [18] [19] [20] and early clinical trials in humans [21] [22] [23] [24] have shown the benefits of BNP1-32 in the treatment of CHF. This led to the registration of Nesiritide in the United States (Natrecor; Scios, Inc, Mountain
View, California), a recombinant human BNP1-32 product, for IV use in people with decompensated CHF displaying clinical signs of dyspnea at rest.
Despite its initial success, an ultimate reduction in the rate of case fatalities or rehospitalization was not observed in humans with CHF. 25 This caused Nesiritide to fall out of favor in human medicine and likely contributed toward reduced interest for use in companion animals.
Another limiting factor is its formulation-an injectable preparationwhich has traditionally resulted in use as an IV drug. Yet, there is growing evidence of its safety and efficacy when administered SC. 16, 18, 23, 24, 26, 27 SC administration facilitates its use in chronic treatment, and its potential role in the treatment of subclinical heart disease 28 Although no solid conclusions to support its benefits in these contexts have been reported to date, there is enough theoretical and experimental data to support further investigation into its use in dogs with naturally occurring CHF caused by MMVD.
In this study, the cardiorenal and endocrine effects of synthetic canine BNP1-32, given SC with or without furosemide, were evaluated in dogs with compensated CHF caused by MMVD.
| MATERIALS AND METHODS

| Animals
Seven client-owned geriatric (10.5-17 years old) male dogs with compensated American College of Veterinary Internal Medicine (ACVIM) stage C (chronic) CHF caused by MMVD were recruited in this study.
Ethics approval was obtained from the University of Sydney Animal
Ethics Committee before commencement of the study (approval number 2016/1113). 
| Study design
| Study outline
After enrolment, dogs presented to the UVTHS on 3 days, each 2 weeks apart, for this study. Benazepril was dosed once daily at night, including the night before each visit. The morning doses of pimobendan and furosemide were withheld on each study day. On the morning of each visit, history and physical examinations were performed to ensure well-being of the dogs, and peripheral IV and indwelling urinary catheters were placed. At the end of a 1-hour control period, heart rate (HR), BP, and urine output (UOP) were measured; blood and urine samples were collected for endocrine, electrolyte, biochemistry, and cGMP testing. The amount of blood collected was replaced with 7 mL saline. One of the following treatments was administered:
• were measured in triplicate and averaged before statistical analysis. however, samples treated and held under similar conditions were reportedly stable in human plasma samples for 6 months for BNP-32 30 and plasma and urinary cGMP. [31] [32] [33] Furthermore, aldosterone concentrations in human serum control samples stored at −30 C at the particular laboratory consulted for aldosterone assays were noted to be stable for at least 9 months, with no drift observed at 0.12 and 0.68 nM/L (n = 78).
| Sample processing and storage
| Blood and urine analysis
Plasma immunoreactive BNP-32 concentrations were measured at a commercial laboratory (Phoenix Pharmaceuticals, Inc) using a vali- Readings made at 540 nm were subtracted from those made at 450 nm.
A standard curve was generated using a 4-parameter logistic curve fit using GraphPad Prism V7.02 (La Jolla, California). Measured concentrations were derived using this standard curve and multiplied by the dilution factor. All samples and standards were assayed in triplicate, all controls in duplicate, and results were averaged for analysis. All standard curves had R 2 > 0.987. The %CV of standard, sample, and control replicates were <10%, and the %CV of standards between plates were <10%. Each control fell within the expected concentration range. Plasma concentrations of cGMP were reported in pM/mL. In order to account for differences in concentration due to rate of urine production, urinary excretion of cGMP (UEcGMP; pM/kg/min) was also calculated by multiplying the UOP by the urinary concentration of cGMP.
Plasma and urine sodium (Na), potassium (K), and creatinine concentrations were measured at a commercial veterinary diagnostic laboratory (Veterinary Pathology Diagnostic Service, University of Sydney, Australia). Fractional excretion of sodium (FE Na ) and potassium (FE K ) were calculated using the formula:
where X indicates sodium or potassium.
Plasma concentrations of aldosterone were determined at the Radboud University Medical Centre laboratory (Nijmegen, the Netherlands) using a validated aldosterone assay involving ultra-high- Significance was set at α of 0.05. If the interaction term was significant, significant interactions were identified using the least square difference method post hoc. If this term was not significant, it was dropped from the model. Model assumptions were assessed through visual inspection of residual plots.
| Statistical analysis
| RESULTS
Breeds represented in the study cohort included the Cavalier King
Charles Spaniel (n = 2), Kelpie, Maltese cross, Jack Russell Terrier cross, and Miniature Poodle cross (n = 2). Baseline characteristics and doses of medications have been summarized in Table 1 . At the time of the first study day (visit 1), dogs had been on treatment with furosemide for a median of 59 days (range 18-133 days), pimobendan for 63 days (range 26-252 days), and benazepril for 33 days (range
16-62 days). The median number of days between the diagnosis of CHF and the first study day was 59 days (range 18-133 days).
A deviation from the protocol occurred during visit 1 (BNP treatment) in 1 dog when urine samples were erroneously collected from the end of an extension line holding 10 mL of volume which was attached to the urinary catheter instead of emptying the contents of the line each time. As the line was filled with urine before collection of data, the measurement of UOP was not affected. However, the volume held in this line exceeded the amount of urine production in each hour; thus, urinary analyte concentrations did not accurately reflect expected concentrations for the period in which the sample was taken. As such, urinary endocrine, cGMP, and fractional excretions at visit 1 for this dog were not calculated, and these data were excluded from the overall analysis.
Administration of synthetic canine BNP1-32 was well tolerated by all dogs in the study. There were no systemic or local adverse effects encountered during the study. FIGURE 2 Urinary excretion of cGMP (pM/kg/min; graph A) and fractional excretions of sodium (FE Na , %; graph B) and potassium (FE K , %; graph C) after administration of BNP1-32 (5 μg/kg, solid black line), furosemide (2 mg/kg, solid gray line), or BNP1-32 + furosemide (5 μg/kg + 2 mg/kg, dashed black line) SC in 7 dogs with chronic congestive heart failure caused by myxomatous mitral valve disease. The median and range were plotted. Asterisks denote significant (P < .05) differences between BNP1-32 and furosemide (*); BNP1-32 and BNP1-32 + furosemide (**); and BNP1-32 + furosemide and furosemide (***). Hats denote significant (P < .05) differences from baseline for BNP1-32 (^); furosemide (^^); and BNP1-32 + furosemide (^^^) zero, or estimating these values to be half the LLOQ. 35 As the data was not missing, and as aldosterone concentrations would not be expected to be zero from a biological perspective, the value of half the LLOQ was assigned where concentrations < LLOQ were obtained, and plasma aldosterone concentrations were graphically depicted ( Figure 3 ).
| Effect of treatments on cardiorenal variables
The UOP increased significantly from baseline after administration of FRUS and FRUS/BNP and remained increased at the end of the study; in contrast, BNP alone did not result in changes to UOP (Figure 4 ).
Maximal effects were reached at 1 hour after treatment in the FRUS and FRUS/BNP groups, with a 1246% and 887% increase in median UOP compared to baseline, respectively. Though these treatments resulted in significantly higher UOP compared to BNP, there were no differences between the 2 furosemide containing treatments. None of the treatments resulted in significant changes in HR or BP ( Figure 5 ).
| DISCUSSION
This is a report of a prospective study evaluating the cardiorenal and endocrine effects and tolerability of single doses of synthetic canine BNP1-32 given SC to dogs with compensated ACVIM stage C CHF caused by MMVD. BNP1-32 was well tolerated, and after subcutaneous dosing, it was well absorbed and resulted in an increase in UEcGMP; however, there were no measurable effects on biological outcomes (UOP, BP, HR, FE Na/K , and plasma aldosterone concentration) in this study. mediates cellular effects has yet to be discovered, there is evidence to support involvement of cGMP-dependent protein kinases (PKG) [41] [42] [43] and amiloride-sensitive cation channels 43 in the generation of natriuretic peptide-induced vasodilation, natriuresis, and diuresis. In addition, phosphodiesterase 5 inhibition to reduce cGMP hydrolysis appears to be of benefit in the face of CHF and augments effects of exogenous BNP1-32. 19, 26, [44] [45] [46] Alternatively, the biological effects of BNP1-32 might have been obscured in the present study due to aspects relating to its study design. The labeled use of Nesiritide in people is for acutely decom- and the possibility for reduced RAAS activation in the chronic, stable phase of CHF. 49 Despite this, both treatments containing BNP1-32 appeared to demonstrate an initial suppression and then a rise in aldosterone concentrations on visual inspection of Figure 3 . This observation is weak but is in contrast to previous reports of aldosterone suppression after BNP1-32 administration in people with CHF 23 and in dogs with furosemide-induced RAAS activation. 17 As a final note, the cGMP and aldosterone assays employed in this study should ideally have been fully validated for use on canine plasma and urine samples.
Instead, formal validation was performed by the manufacturers of the assays utilizing samples from other species (humans and rodents), and partial validation and quality control monitoring of canine samples were employed during the course of this study. Yet, with the molecular structure of both cGMP and aldosterone being conserved between species, it is expected that the assays will perform similarly in samples from different species. These tests were thus deemed fit for use for the purposes of this study.
In summary, SC administered synthetic canine BNP1-32 was well- 
